Skip to content
Ejaculation.org

Systematic review · 2025

Pharmacological Interventions in Primary or Secondary Male Anorgasmia: A Systematic Review

Gómez-Bueno MP, Diaz-Hung AM, García-Perdomo HA (2025). Pharmacological Interventions in Primary or Secondary Male Anorgasmia: A Systematic Review. Actas Urológicas Españolas. doi:10.1016/j.acuroe.2025.501835

Key finding
Across 7 studies of 234 men with anorgasmia, cabergoline (the most-used drug) improved orgasm in 66% and yohimbine in 55%; bupropion also improved orgasm scores, and side effects were mostly mild.

Summary

This systematic review, following Cochrane recommendations and the PRISMA statement, looked for studies of drug treatment in men over 18 with primary (lifelong) or secondary (acquired) anorgasmia, the inability to reach orgasm. It found seven studies with 234 men, 232 of whom were treated with medication. Reported backgrounds included prostate removal, low testosterone, psychiatric conditions and antidepressant use.

Cabergoline was the most frequently used drug, followed by yohimbine and bupropion. Cabergoline improved orgasm in 66% of men and yohimbine in 55%. Orgasmic function scores on the International Index of Erectile Function improved significantly with cabergoline and bupropion. Side effects were reported as mild in three studies, while amantadine had to be stopped because of depression.

Limitations

Seven mostly small studies, many observational, with different drugs and populations, cannot establish which drug works best. Risk of bias was assessed but the evidence base remains weak.

What it means for you

Some men with delayed or absent orgasm improve on medicines such as cabergoline or bupropion, prescribed off-label by a specialist. The evidence is promising but early, so these drugs are an option to discuss, not a first step.